Afatinib - Boehringer Ingelheim

Drug Profile

Afatinib - Boehringer Ingelheim

Alternative Names: BIBW 2992 MA2; BIBW-2992; Gilotrif; Giotrif; Tomtovok; Tovok; Xovoltib

Latest Information Update: 30 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; European Organisation for Research and Treatment of Cancer; European Thoracic Oncology Platform; H. Lee Moffitt Cancer Center and Research Institute; Hanshin Oncology Group; Leiden University Medical Center; Okayama University
  • Class Antineoplastics; Quinazolines; Radiation-sensitising agents; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer; CNS cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase III Breast cancer; Head and neck cancer
  • Phase II Chordoma; Glioma; Pancreatic cancer; Urogenital cancer
  • Phase I/II Rhabdomyosarcoma
  • Phase I Glioblastoma
  • No development reported Colorectal cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 27 Jul 2018 CTP Push 282909- Updated KDM, org table and dev T, added respective HE
  • 22 Jul 2018 Boehringer Ingelheim completes a phase II trial in Non-small cell lung cancer (Late-stage disease, Monotherapy, Combination therapy, Second-line therapy or greater) in China, Malaysia (PO) (NCT02597946)
  • 06 Jul 2018 Boehringer Ingelheim completes the phase III LUX-Breast 1 trial in Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) is ongoing in USA, Canada, Chile, Argentina, Brazil, Mexico, Peru, South Africa, Australia, European Union, Belarus, Japan, Singapore, South Korea, Taiwan, China, Egypt, Israel, Turkey, Lebanon, Russia, Sri Lanka and India (NCT01125566) (EudraCT2009-015476-98)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top